Patents Assigned to Pfizer
  • Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
    Patent number: 7091372
    Abstract: The present invention relates to processes for the preparation of any of the intermediate 1,3-substituted indenes of the formulae (Ia), (Ib) and (Ic) or a mixture thereof: wherein R1, R2, R3, R4, and R5 are defined herein. Compounds of formulae (Ia), (Ib) and (Ic) or mixtures thereof are useful in the preparation of compounds of formula (II): wherein R2, R3 and R6 are also defined herein.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: August 15, 2006
    Assignee: Pfizer Inc
    Inventors: Robert A. Singer, Jason D. McKinley
  • Enzyme PDE XVI
    Patent number: 7091024
    Abstract: Amino acid sequences and nucleotide sequences relating to PDE_XIV are described. In a preferred aspect, the amino acid sequences comprise the sequence presented as SEQ ID NO:1 or SEQ ID NO:3 or SEQ ID NO:5.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: August 15, 2006
    Assignee: Pfizer Inc.
    Inventor: Mark D. Fidock
  • Human phosphodiesterase IV isozymes
    Patent number: 7087734
    Abstract: This invention relates to novel nucleic acid sequences encoding three novel human phosphodiesterase (hPDE IV) isozymes. It also relates to polypeptides encoded by such sequences. This invention also relates to an assay method for detecting the presence of such novel isozymes in human cells, and to a method of identifying compounds or other substances that inhibit or modify the activity of such isozymes.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: August 8, 2006
    Assignee: Pfizer, Inc.
    Inventors: Douglas A. Fisher, Michael D. Robbins
  • Substituted pyrimidine derivatives
    Patent number: 7087617
    Abstract: This invention relates to compounds of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.
    Type: Grant
    Filed: May 5, 2004
    Date of Patent: August 8, 2006
    Assignee: Pfizer Inc.
    Inventors: Jeffrey W. Corbett, Michael Dalton Ennis, Kristine E. Frank, Jian-Min Fu, Robert Louis Hoffman, Patrick R. Verhoest
  • Monoamine reuptake inhibitors for treatment of CNS disorders
    Patent number: 7084165
    Abstract: The present invention relates to compounds that are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.
    Type: Grant
    Filed: September 4, 2003
    Date of Patent: August 1, 2006
    Assignee: Pfizer Inc
    Inventors: Harry Ralph Howard, Jr., Christopher Joseph Schmidt, Thomas Francis Seeger, Mark Leonard Elliot
  • 3-Amino-piperidine derivatives and methods of manufacture
    Patent number: 7084277
    Abstract: This invention relates to 3-amino piperidine derivatives, their intermediates and methods of manufacture. As such, the present invention includes methods of making a compound of the formulas (Ia) and (Ib) wherein R1, R2, R3, R4, R14, and n are herein defined. The present invention also relates to the compounds used in such processes, as well as the compounds made by the processes.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: August 1, 2006
    Assignee: Pfizer Inc.
    Inventor: David H. B. Ripin
  • Triazole compounds useful in therapy
    Patent number: 7084145
    Abstract: The invention provides compounds of formula (I), the pharmaceutically acceptable salts and solvates thereof, wherein A, B, R1, R2, and R7 are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof as vasopressin V1A antagonists.
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: August 1, 2006
    Assignee: Pfizer Inc.
    Inventors: Robert Duncan Armour, Andrew Douglas Baxter, Justin Stephen Bryans, Kevin Neil Dack, Patrick Stephen Johnson, Russell Andrew Lewthwaite, Julie Newman, David James Rawson, Thomas Ryckmans
  • Retroviral protease inhibitors
    Publication number: 20060166895
    Abstract: N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
    Type: Application
    Filed: January 13, 2006
    Publication date: July 27, 2006
    Applicant: Monsanto Company (now named Pharmacia Corporation, which is a wholly owned subsidiary of Pfizer, Inc
    Inventors: John Talley, Daniel Getman, Gary DeCrescenzo, Kathryn Reed, Ko-Chung Lin, John Freskos, Michael Clare, Donald Rogier, Robert Heintz, Michael Vazquez, Richard Mueller
  • Crystal forms of azithromycin
    Patent number: 7081525
    Abstract: The invention relates to novel crystal forms of azithromycin, an antibiotic useful in the treatment of infections.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: July 25, 2006
    Assignee: Pfizer Inc.
    Inventors: Zheng J. Li, Andrew V. Trask
  • Imidazole derivatives
    Patent number: 7078529
    Abstract: The invention provides compounds of formula 1 wherein R1, R2, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission.
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: July 18, 2006
    Assignee: Pfizer Inc.
    Inventors: Mark A. Sanner, Chris J. Helal, Christoper B. Cooper, Frank S. Menniti, Patricia A. Seymour, Michael K. Ahlijanian, Anabella Villalobos, Lit-Fui Lau
  • Pyrrolo[1,2-b]pyridazine compounds and their uses
    Patent number: 7074791
    Abstract: Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression. CRF receptor antagonists of the invention have the structure of formula (I): including stereoisomers or mixture of stereoisomers, pharmaceutically acceptable prodrugs, or pharmaceutically acceptable salts thereof, wherein in formula (I) R1 and R2 are independently selected from H, Me or OMe.
    Type: Grant
    Filed: October 9, 2003
    Date of Patent: July 11, 2006
    Assignee: Pfizer Inc.
    Inventor: Jian-Min Fu
  • Certain alkylene diamine-substituted heterocycles
    Patent number: 7074929
    Abstract: This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: July 11, 2006
    Assignees: Neurogen Corp., Pfizer, Inc.
    Inventors: Raymond F. Horvath, Jennifer Tran, Stéphane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
  • CETP inhibitors in combination with antihypertensive agents and uses thereof
    Patent number: 7071210
    Abstract: This invention relates to pharmaceutical combinations of a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceutically acceptable salt thereof; and an antihypertensive agent or a pharmaceutically acceptable salt thereof, optionally in combination with an HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetaliproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal (including a human being either male or female).
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: July 4, 2006
    Assignee: Pfizer Inc.
    Inventor: Roger B. Ruggeri
  • Benzamide inhibitors of the P2Xreceptor
    Patent number: 7071223
    Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1–R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    Type: Grant
    Filed: December 30, 2003
    Date of Patent: July 4, 2006
    Assignee: Pfizer, Inc.
    Inventors: Mark A Dombroski, Allen J. Duplantier, Chakrapani Subramanyam
  • Macrolide antibiotics
    Patent number: 7071170
    Abstract: This invention relates to compounds of the formula wherein a, R1, R2, R3, R4, R5, R6 and X are each as defined above, and to pharmaceutically acceptable salts thereof, useful as potent antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating bacterial and protozoal infections by administering the compounds of formula I.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: July 4, 2006
    Assignee: Pfizer Inc.
    Inventor: Takushi Kaneko
  • Directly compressible formulations of azithromycin
    Patent number: 7070811
    Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: July 4, 2006
    Assignee: Pfizer Inc.
    Inventors: Brendan Murphy, Steven W. Collier, Ernest Quan, Barbara A. Johnson
  • Matrix metalloproteinase polypeptide
    Patent number: 7070976
    Abstract: The present invention provides genes encoding novel matrix metalloproteinases termed MMP; constructs and recombinant host cells incorporating the genes; the MMP polypeptides encoded by the genes; antibodies to the MMP polypeptides; and methods of making and using all of the foregoing.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: July 4, 2006
    Assignee: Pfizer Inc.
    Inventors: Timothy Wood, Jonas Ekblom, Erik Holmgren, Mats Kihlén
  • Benzoimidazole derivatives useful as antiproliferative agents
    Patent number: 7071337
    Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R2, R3, and R4 are as defined herein. The invention also relates to methods of treating abnormal cell growth, such as cancer, in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
    Type: Grant
    Filed: August 26, 2003
    Date of Patent: July 4, 2006
    Assignee: Pfizer Inc
    Inventors: John C. Kath, Joseph P. Lyssikatos, Huifen Faye Wang
  • Sertraline oral concentrate
    Patent number: 7067555
    Abstract: The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: June 27, 2006
    Assignee: Pfizer Inc
    Inventors: Nancy J. Harper, Gautam R. Ranade, Willard M. Welch
  • 2-amino-pyridine derivatives useful for the treatment of diseases
    Patent number: 7067541
    Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: June 27, 2006
    Assignee: Pfizer Inc
    Inventors: Alan Daniel Brown, Justin Stephen Bryans, Charlotte Alice Louise Lane, Simon John Mantell